Translational Oncology and Herbal Immunomodulators

Abstract

Integrative oncology has moved from a niche concern to a standard feature of patient conversations across European cancer centres, driven by the combination of patient interest, supportive-care evidence for selected complementary agents, and the slow accumulation of immunomodulatory mechanistic data for classical Ayurvedic herbs. Translational oncology interest has centred on herbs with documented effects on NK cell activity, macrophage polarisation, T-cell balance and cytokine signalling, including Withania somnifera (Ashwagandha), Tinospora cordifolia (Guduchi), Curcuma longa (curcumin), Ocimum sanctum (Tulsi), and classical rasayana polyherbal preparations. This study reviewed 70 primary mechanistic, preclinical and clinical studies published between 2005 and 2021 covering herbal immunomodulators with demonstrated or proposed oncology relevance, grouped under five translational frames: O1 (direct single-herb anti-tumour activity), O2 (immunomodulatory adjuvants during chemotherapy), O3 (post-chemotherapy immune recovery), O4 (anti-tumour immunity and checkpoint modulation), and O5 (integrated multi-herb rasayana oncology protocols). Each frame was scored using the Translational Oncology-Immunomodulation Index (TOI), a weighted composite across mechanistic evidence, clinical evidence, oncology-treatment safety, therapeutic yield, and integration with standard care. Post-chemotherapy immune recovery adjuncts (O3) and integrated multi-herb oncology protocols (O5) produced the highest TOI values (0.852 and 0.836 respectively), driven by their particularly strong supportive-care clinical evidence. Single-herb direct anti-tumour activity (O1, TOI 0.778) has substantial mechanistic weight but limited clinical deployment evidence. Immune checkpoint modulation (O4, TOI 0.672) is the earliest-stage frame.